Mark Newman, Author at Endocrine News

Unpausing the Conversation: Menopause is Having a Moment at ENDO 2026

Women’s bone health takes center stage in Chicago during the symposium “Hot and Flashy: Topics in Menopause,” on Saturday June 13. From catching endocrinologists up regarding menopause care and past regulatory missteps to estrogen’s impact on bone health and the myriad non-hormonal options, this ENDO 2026 symposium will definitely give attendees something to talk about!...

Pharma Fridays

Pharma Friday – May 22, 2026

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Lilly’s Retatrutide Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial On May 21, Eli Lilly and Company, the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy...

Breaking Point: Weight Loss Therapies and the Musculoskeletal Stakes

ENDO 2026 attendees who catch the session, “Weight Loss: Friend or Foe for Bone & Muscle?” will be in for a treat as three experts weigh in on the impact of various weight loss therapies on muscle and bone. Pharmacological, surgical, and even lifestyle impacts will be discussed and debated in this Sunday morning symposium....

Guiding Curiosity: Talking with 2026 Outstanding Mentor Award recipient, Patricia Lee Brubaker, PhD

When Patricia Lee Brubaker, PhD, the Endocrine Society’s 2026 recipient of the Outstanding Mentor Laureate Award, was interviewing potential candidates to join her laboratory, she always kept in mind that she needed to choose someone she really liked as well as respected. Mentorship is one of the most powerful forces in shaping scientific careers —...

Society News

Endocrine Society, Keystone Symposia to Host First Joint Conference in October

Researchers can register and submit abstracts for the first joint meeting hosted by the Endocrine Society and Keystone Symposia — an intimate meeting designed to bring together researchers to advance understanding of how hormonal signaling shapes cancer risk, progression and treatment response. Hormonal Influences on Immunity and Cancer Across the Lifespan, taking place in October in Breckenridge, Colo., will be the first of three joint meetings held by the organizations, which...

Member News

Daniel J. Drucker, MD, Receives the 2026 Lefoulon-Delalande Foundation Scientific Prize

Endocrine Society member Daniel J. Drucker, MD, and Jens Juul Holst, MD, DMSc, have been honored with the 2026 Lefoulon-Delalande Foundation Scientific Prize from the Institut de France for their work on GLP-1s, a key hormone in metabolic regulation. Each year, the Lefoulon-Delalande Foundation awards its Scientific Prize to a scientist who has made a...

Pharma Fridays

Pharma Friday – May 15, 2026

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution On May 13, Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for its...

ENDO 2026 Preview: Beyond Basic DXA

At ENDO 2026, taking place June 13 – 16 in Chicago, “Beyond Basic DXA” is set to challenge how clinicians think about bone health assessment. Angela M. Cheung, MD, PhD, a professor of medicine at the University Health Network and the University of Toronto, will lead “Beyond Basic DXA” on Day 4 (Monday, June 15),...